Biopharmaceutical - Immunotherapy and Monoclonal Antibodies
Strategic Profile
Barzo is uniquely positioned as a "pipeline in a drug," targeting multiple mast cell diseases and commanding potential premium pricing. Management suggests that barzo's durable efficacy—extending beyond a year of dosing—could support substantially higher reimbursement, comparable to Dupixent's $60,000 annual cost.
Cyborg Score Rationale
Celldex recently announced the completion of enrollment in the Company's global Phase 3 program in CSU, which fully accrued six months ahead of guidance, with 1,939 patients enrolled—the largest program conducted in antihistamine refractory CSU. Based on analyst ratings, Celldex Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $44.20.
Top Insights
Phase 2 open-label extension data shows complete response rates at Week 20 of 62% (ColdU) and 60% (SD), with repeat complete response reaching 82% (ColdU) and 86% (SD) among prior responders.
Topline Phase 3 data expected Q4 2026 with BLA submission planned for 2027.
Stifel Nicolaus reissued a "buy" rating and set a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics.
Recent Q4 2025 financials disappointed with the company missing EPS and revenue expectations, reporting very large negative margins and negative ROE.
Named Competitors
Dupixent — Currently used for similar allergic/inflammatory indications with ~$60,000 annual pricing
Other Antihistamines — Existing first-line treatments for urticaria that barzolvolimab may improve upon
Recent Developments
(Mar 2026) Presented positive Phase 2 open-label extension data on barzolvolimab retreatment in Cold urticaria and symptomatic dermographism at AAAAI 2026.
(Feb 2026) Completion of enrollment in two large EMBARQ-CSU Phase 3 trials with 1,939 patients coincided with a 24.07% stock gain.
(Feb 2026) Reported Q4 2025 quarterly earnings with ($1.22) EPS, missing consensus estimate by ($0.22), and revenue of $0.12 million versus expected $1.53 million.
Open the full interactive Celldex Therapeutics report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.